A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Phase 3Active, not recruiting
- Lead sponsor
- CG Oncology, Inc. (Industry)
- Enrollment
- 367 (actual)
- Start date
- 14 Dec 2023
- Primary completion
- Nov 2026 (estimated)
- Study completion
- 1 Feb 2029
- Last update posted
- 1 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Cretostimogene Grenadenorepvec Drug
- n-dodecyl-B-D-maltoside Other
Conditions and primary outcome
- Non Muscle Invasive Bladder Cancer
- Urologic Cancer
- Bladder Cancer
- Urothelial Carcinoma
Primary outcome
Recurrence Free Survival (RFS) (29 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06111235.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06111235 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.